Skip to main content
. 2023 Apr 7;12(8):1103. doi: 10.3390/cells12081103

Figure 2.

Figure 2

A scheme of CRISPR-Cas9 engineering in autologous CAR-T therapy. T cells are extracted from cancer patients and engineered with CRISPR-Cas9 to edit select genes. Later, chimeric antigen receptor (CAR) is randomly inserted into the genome via lentivirus or precisely engineered into a target locus via the CRISPR-Cas9 system to create an engineered autologous CAR-T cell. Engineered CAR-T cells are later given back to the cancer patients.